Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

0.6472 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9
Open 0.6472
Bid (Size) 0.6473 (1)
Ask (Size) 0.6687 (59)
Prev. Close 0.6472
Today's Range 0.6472 - 0.6472
52wk Range 0.5150 - 2.080
Shares Outstanding 257,328,085
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
From Ocugen
Via GlobeNewswire
Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire

Performance

YTD
-28.1%
-28.1%
1 Month
+7.0%
+7.0%
3 Month
-19.6%
-19.6%
6 Month
-31.9%
-31.9%
1 Year
-58.0%
-58.0%

More News

Read More
Beyond The Numbers: 5 Analysts Discuss Ocugen Stock
Via Benzinga
Expert Outlook: Ocugen Through The Eyes Of 4 Analysts
Via Benzinga
Navigating 4 Analyst Ratings For Ocugen
Via Benzinga
Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates
Via Stocktwits
Ocugen (OCGN) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
From Ocugen
Via GlobeNewswire
Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease
From Ocugen
Via GlobeNewswire
Earnings Scheduled For March 5, 2025
Via Benzinga
Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ: OCGN)
From Grabar Law Office
Via GlobeNewswire
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
From Ocugen
Via GlobeNewswire
Grabar Law Office Is Investigating Claims On Behalf Of Long-Term Shareholders Of Atkore Inc. (NYSE: ATKR); Crocs, Inc. (NASDAQ: CROX); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ: OCGN)
From Grabar Law Office
Via GlobeNewswire
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
From Ocugen
Via GlobeNewswire
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
From Ocugen
Via GlobeNewswire
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
From Ocugen
Via GlobeNewswire
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
From Ocugen
Via GlobeNewswire
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
Shankar Musunuri, CEO of Ocugen Inc. (NASDAQ: OCGN), to Present at NobleCon20
Via Investor Brand Network

Frequently Asked Questions

Is Ocugen, Inc. - Common Stock publicly traded?
Yes, Ocugen, Inc. - Common Stock is publicly traded.
What exchange does Ocugen, Inc. - Common Stock trade on?
Ocugen, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ocugen, Inc. - Common Stock?
The ticker symbol for Ocugen, Inc. - Common Stock is OCGN on the Nasdaq Stock Market
What is the current price of Ocugen, Inc. - Common Stock?
The current price of Ocugen, Inc. - Common Stock is 0.6472
When was Ocugen, Inc. - Common Stock last traded?
The last trade of Ocugen, Inc. - Common Stock was at 04/01/25 04:00 PM ET
What is the market capitalization of Ocugen, Inc. - Common Stock?
The market capitalization of Ocugen, Inc. - Common Stock is 166.54M
How many shares of Ocugen, Inc. - Common Stock are outstanding?
Ocugen, Inc. - Common Stock has 167M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.